You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 16, 2024

Claims for Patent: 7,008,923

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,008,923

Title:	Glycopeptide phosphonate derivatives
Abstract:	Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s):	Leadbetter; Michael R. (San Leandro, CA), Linsell; Martin S. (San Mateo, CA)
Assignee:	Theravance, Inc. (South San Francisco, CA)
Application Number:	11/037,934
Patent Claims:	1. A method of treating a staphylococcal infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of the formula: ##STR00009## or a pharmaceutically-acceptable salt thereof. 2. The method of claim 1, wherein the staphylococcal infection is caused by Staphylococcus aureus. 3. The method of claim 1, wherein the staphylococcal infection is caused by Staphylococcus epidermidis. 4. The method of claim 1, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus. 5. The method of claim 1, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis. 6. The method of claim 1, wherein the compound is administered intravenously. 7. The method of claim 1, wherein the pharmaceutically-acceptable salt is a hydrochloride salt. 8. A method of treating a staphylococcal infection in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula: ##STR00010## or a pharmaceutically-acceptable salt thereof. 9. The method of claim 8, wherein the pharmaceutical composition further comprises a cyclodextrin. 10. The process of claim 9, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin. 11. The process of claim 9, wherein the cyclodextrin is sulfobutyl ether .beta.-cyclodextrin. 12. The method of claim 8, wherein the staphylococcal infection is caused by Staphylococcus aureus. 13. The method of claim 8, wherein the staphylococcal infection is caused by Staphylococcus epidermidis. 14. The method of claim 8, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus aureus. 15. The method of claim 8, wherein the staphylococcal infection is caused by methicillin-resistant Staphylococcus epidermidis. 16. The method of claim 8, wherein the pharmaceutical composition is administered intravenously. 17. The method of claim 1, wherein the pharmaceutically-acceptable salt is a hydrochloride salt. 18. A method of treating a staphylococcal infection in a mammal where the infection is caused by methicillin-resistant Staphylococcus aureus, the method comprising administering a therapeutically effective amount of a composition comprising: (A) a compound of the formula: ##STR00011## or a hydrochloride salt thereof; and (b) hydroxypropyl-.beta.-cyclodextrin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.